Trial Profile
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Synta Pharmaceuticals
- 25 Sep 2023 Planned End Date changed from 1 Dec 2018 to 1 Dec 2024.
- 25 Sep 2023 Status changed to active, no longer recruiting, according to ClinicalTrials.gov: US National Institutes of Health
- 10 Dec 2018 Status changed from active, no longer recruiting to completed.